about
Our mission at Consano Bio is to improve the lives of people living with painful and debilitating orthopedic conditions. We are developing C-1101, an Allogenic Multi-Protein Therapeutic engineered to target the drivers of disease, rather than the symptoms.
leadership
Consano Bio is led by a management team with deep clinical, regulatory and commercial experience in biologic drug development. Collectively they have delivered over 30 Investigational New Drug (IND) submissions and over 10 FDA product approvals across multiple innovative therapeutics.
Andrew Hall, MS
Chief Executive Officer and Board Member
Jennifer Schmitke, PhD
Chief Development Officer and Head of R&D
board of
directors
Board Members
Doug Vander Weide
Dr. Chris Centeno
Bill Abbington
Dr. Jerome Adams
Andrew Hall, MS
Andrew Hall, MS
Chief Executive Officer and Board Member
Andrew brings significant experience as a company builder, dealmaker and drug developer in the biotechnology industry. Andrew previously led IMV Inc., a clinical-stage biopharmaceutical company in oncology that was acquired in 2023. Before IMV, Andrew spent 7 years at Celgene, where he led corporate development and pipeline strategy for immunology, as well as business development and strategic alliances, working on deals from discovery to commercialization. Before that, Andrew spent more than 15 years at Merck, BMS and Schering Plough in leadership roles across Asia Pacific, Europe and the United States. Through all these experiences, Andrew has developed expertise across multiple disease spaces, major geographies and end-to-end drug development. Andrew holds a Master of Science from RMIT University and a Bachelor of Medical Science (honors) from Melbourne University.
Jennifer Schmitke, PhD
Chief Development Officer and Head of R&D
Jen is an accomplished biopharma executive with experience leading R&D teams from early start-ups to large biotechs. Jen was previously Senior Vice President, Technical Operations, Quality, and Portfolio Management at Epizyme, a commercial-stage biopharma oncology company, where she led the prioritization of the corporate R&D portfolio. Before that, she was Vice President for program management at Magenta Therapeutics and drove the build-out of the portfolio and program management functions and supporting governance. Before her tenure at Magenta Therapeutics, Dr. Schmitke was at Omega Therapeutics, where she helped build the company and research pipeline from the ground up. Additionally, Jen was a Senior Director at Biogen in early pipeline leadership and spent many years at Alkermes where she held a series of roles of increasing responsibility in technical development and CMC leadership. Through all these experiences, Jen has developed deep expertise in CMC, non-clinical development, clinical development, and portfolio strategy. Jen holds a Bachelor of Science in Chemistry with honors from Queen’s University in Ontario, Canada, and a PhD in Biological Chemistry from Massachusetts Institute of Technology.